ACRV - Acrivon Therapeutics, Inc.
1.66
0.060 3.614%
Share volume: 520,286
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$1.60
0.06
0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-13-2024 | 03-27-2025 | 05-14-2025 | 11-13-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | ||||
| Operating expenses | 17.668 M | 21.437 M | 25.140 M | 24.954 M | 21.662 M | 19.687 M | |
| Selling general and admin | 6.195 M | 6.412 M | 6.276 M | 6.324 M | 6.248 M | 6.039 M | |
| Research and development | 11.473 M | 15.025 M | 18.864 M | 18.630 M | 15.414 M | 13.648 M | |
| Total expenses | 17.668 M | 21.437 M | 25.140 M | 24.954 M | 21.662 M | 19.687 M | |
| 21.33% | 17.27% | -0.74% | -13.19% | -9.12% | |||
| Operating income | -17.668 M | -21.437 M | -25.140 M | -24.954 M | -21.662 M | -19.687 M | |
| Ebit | -17.932 M | -21.492 M | -25.139 M | -25.194 M | -21.676 M | -19.740 M | |
| Pretax income | -16.486 M | -18.798 M | -22.441 M | -22.831 M | -19.680 M | -18.234 M | |
| 14.02% | 19.38% | 1.74% | -13.80% | -7.35% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -16.486 M | -18.798 M | -22.441 M | -22.831 M | -19.680 M | -18.234 M | |
| -14.02% | -19.38% | -1.74% | 13.80% | 7.35% |